positive predictive value (PPV) of isoniazid resistance for determining ethionamide resistance were calculated. Subgroup analysis to determine the rate of ethionamide resistance in low-and high-level isoniazid-resistant MTB strains was also calculated. Exemption to ethical approval was granted by the Ethical Review Committee, Aga Khan University.
results
During the study period, records of 17,184 strains were recovered from the laboratory database. Among these, isoniazid and ethionamide susceptibility data were available for 11,274 MTB strains which were included in the analysis, whereas 5910 strains had incomplete information and were excluded from the study. Strains from all across Pakistan were included; 3080 isolates from Karachi, 1437 from Lahore, 1187 from Peshawar, 145 from Islamabad, and 505 from Quetta.
Out of 11,274 strains, 5939 were isoniazid resistant (including both low level and high level) and 5335 were isoniazid sensitive. Ethionamide resistance was seen in 629 (5.57%) strains [ Table 1 ].
Sensitivity, specificity, NPV, and PPV of isoniazid resistance as a marker of ethionamide resistance were 93.80%, 49.76%, 99.27%, and 9.93% with a significant P < 0.001. As inhA mutation is associated with low-level isoniazid resistance, we further divided the isoniazid-resistant MTB strains into low-and high-level isoniazid-resistant groups and compared the rate of ethionamide resistance. Our findings showed ethionamide resistance to be 26.6% in low-level isoniazid-resistant MTB strains as compared to 8.85% in high-level isoniazid-resistant MTB strains [ Figure 1 ].
A subgroup analysis was performed by further dividing low-and high-level isoniazid-resistant MTB strains into non-MDR, MDR, preextensively drug-resistant (XDR), and XDR groups. Among strains with low-level isoniazid-resistant (non-MDR, MDR, and pre-XDR) rate of ethionamide resistance was 26%-28% [ Table 2 ]. Moreover, low-level isoniazid resistance was significantly associated with ethionamide resistance (P < 0.001) among all groups except XDR-TB strains.
dIscussIon
TB is a global health concern. According to the WHO report 2015, the prevalence of TB in Pakistan is about 361 cases/100,000. [5] It currently ranks fifth among the high TB burden countries, and although studies have shown nonuniformity in drug resistance rates among different regions in a country, [6] Pakistan still has the fourth highest prevalence of MDR-TB globally. [7] MDR-TB is caused by MTB resistant to at least isoniazid and rifampicin (RIF). Agents used to treat MDR-TB include second-line drugs; amikacin, kanamycin, capreomycin, fluoroquinolones, cycloserine, and thioamides: ethionamide and prothionamide. [8] Ethionamide is readily available in Pakistan and considering its low cost and oral route of administration is one of the frequently used agents to treat MDR-TB. It is available as a pro-drug which undergoes activation by ethA enzyme to convert into its active form. It functions by disrupting the mycobacterial cell wall. Ethionamide is structurally related to isoniazid and both drugs act on the same target site, i.e., inhA protein. inhA protein, encoded by inhA gene, is a nicotinamine adenine dineucleotide-dependent enoyl-acyl carrier protein, responsible for fatty acid chain elongation and mycolic acid synthesis. Association of ethionamide resistance with inhA promoter and gene mutations has been already been explored previously. [9, 10] Our findings are consistent with previous studies which have shown a higher rate of ethionamide resistance among MTB strains with low-level isoniazid resistance and inhA mutation. [11, 12] High incidence of ethionamide resistance in MTB strains showing mutations in inhA promoter and inhA gene has also been reported from a study in India. [13] Genetic diversity among MTB exists, and the distribution of resistance gene may alter in different geographic areas. [14] Molecular tests are recommended by the WHO which can be used to rapidly detect mutations associated with resistance in MTB. These include Xpert MTB/RIF and line probe assays (LPAs). [15] Currently approved Xpert MTB/RIF only detects mutation in the rpoB; however, LPAs can detect mutations in rpoB along with katG and inhA newer version of LPA (MTBDRsl) for second-line drugs has also been approved by the WHO which can detect resistance in fluoroquinolones and injectable anti-TB drugs by detecting mutations in gyrA/ gyrB and rrs/eis, respectively, but does not detect mutations associated with ethionamide resistance. Previous studies have employed LPAs as a rapid means of detecting inhA mutation and associated phenotypic ethionamide resistance. [16] Knowledge regarding the presence or absence of inhA mutation using rapid molecular test such as LPA can be useful in enabling clinicians to decide in a timely manner whether to prescribe ethionamide for the treatment MDR-TB. Since LPAs are increasingly being used as a rapid test for the detection of MDR-TB, our results suggest that in this population, detection of inhA mutations on LPA increases the possibility of ethionamide resistance and highlights the need for drug sensitivity testing. Ethionamide resistance is not only attributed due to mutations in inhA gene but also due to ethA and ethR gene mutations: [17, 18] the ethA protein is itself regulated by ethR protein encoded by the ethR gene. There is thus also a need to explore the presence or absence of these mutations in MTB strains from our region, and to study the extent to which ethionamide resistance in our population is attributed to inhA or ethA/ethR.
Our study is limited by its retrospective nature and a single-center setting. However, the study was conducted on a large sample size and included strains from across the country.
Mutations associated with isoniazid and ethionamide resistance were not explored, and studies evaluating the prevalence of inhA, ethA, and ethR mutations in addition to inhA are needed to better understand the association between ethionamide resistance and low-level isoniazid resistance in this population.
conclusIon
In our population, low-level isoniazid resistance may predict phenotypic ethionamide resistance and hence guide clinicians. However, molecular studies detecting inhA and other mutations are further needed before definitive conclusions can be drawn.
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